Business Wire

KINAXIS

11.1.2024 13:01:50 CET | Business Wire | Press release

Share
Kinaxis Rolls Out New Innovations to Revolutionize Stretched Retail Supply Chains

Kinaxis® Inc. (TSX: KXS), the leading supply chain management platform, today announced an expansion of its retail offering with the release of multiple new AI- and ML-powered innovations that provide retailers with end-to-end supply chain transparency, demand forecasting, and powerful simulation scenario planning capabilities to ensure customers can buy the goods they want, when and where they want them, regardless of unforeseen disruptions.

From unpredictable demand spikes driven by changing consumer habits and the rise of omni-channel commerce that seeks to provide a seamless shopping experience across multiple touchpoints, the retail landscape has never been more competitive, with retailers’ supply chains facing countless challenges that threaten their ability to keep customers happy and turn a profit.

Designed to simplify retailers’ ability to successfully manage the complexity of countless locations, SKUs, promotions and inventory variables that demand unparalleled decision-making, Kinaxis’ enhanced retail offering now includes:

  • Demand.AI innovations – powerful machine-learning based models tailored to the scale and complexity of retailers that enables better understanding of how both internal (e.g. frequent price changes, new product introductions, changes to promotional plans) and external factors (e.g. social sentiment, weather, shifts in consumer behavior, local/national events) are influencing short and long-term demand for their products, and which can inform actions to maximize revenue opportunities and proactively resolve risks.
  • Replenishment Planning – an all-new capability that enables retailers to better manage replenishment parameters across their supply chain to ensure every item at every store and distribution center gets restocked in a timely manner while establishing guardrails to protect stores from shipping excess inventory that would exceed their shelf-life capacity and increase their inventory holding costs.
  • Demand Planning innovations – provides retailers with easy-to-interpret visualizations that explain demand patterns while enabling them to make instant adjustments to forecasts based on human insights around trends at any part of their supply chains, by product, geography, store, SKU, day and more.

“Faced with ever increasing consumer expectations, today’s retailers are in desperate need of solutions that enable them to make confident decisions around their supply chains at scale,” said Andrew Bell, chief product officer at Kinaxis. “With these latest innovations, businesses will finally be able to take the guesswork out of demand and replenishment planning with a view to creating a seamless and resilient end-to-end supply chain. And with additional investments on the horizon in promotion planning and allocation, we’re confident that retailers will continue to look to Kinaxis to help them provide their customers with the best products while ensuring their shelves are always fully stocked.”

The new retail-focused product innovations will enable Kinaxis to strengthen its position within the sector including with new customers like sporting goods leader Brooks Running and existing partners like HAVI, one of the world’s foremost experts in supply chain integration. Last year, Kinaxis and HAVI announced they were joining forces to innovate and transform the Quick Service Restaurant industry.

“With the pace of doing business speeding up and consumer behavior changing by the minute, companies can no longer rely on incremental improvements to their supply chain, which is why we were so thrilled to partner with Kinaxis who have proven their mettle for meeting the demanding needs of customers regardless of the industry,” said Rodney Brown, senior vice president and chief supply chain officer, North America and global planning and analytics at HAVI. “We’re eager to roll out these state-of-the-art capabilities to some of our largest customers and anticipate that they will immediately see the value they bring to their overall business.”

With more than 40,000 users in 100+ countries, Kinaxis works with some of the world’s biggest brands across all sectors including CPG, automotive, high tech, life sciences and more. Its AI-powered technology and patented concurrency technique allows companies to orchestrate their supply chain network end to end from strategic planning to last-mile delivery.

Kinaxis’ retail product innovations will be showcased at NRF 2024 from January 14 – 16, 2024, at the Jacob K. Javits Convention Center in New York City. Visit Kinaxis at Booth #4068.

About Kinaxis

Kinaxis is a global leader in modern supply chain management. We serve supply chains and the people who manage them in service of humanity. Our software is trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. We combine our patented concurrency technique with a human-centered approach to AI to empower businesses of all sizes to orchestrate their end-to-end supply chain network, from multi-year strategic planning through down-to-the-second execution and last-mile delivery. For more news and information, please visit kinaxis.com or follow us on LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240111554461/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye